Analysis of drug dissolution data

Oral Drug Absorption: Prediction and Assessment

Volumn , Issue , 2000, Pages 229-254

  Reppas, Chrtstos ^a   Nicolaides, Eleffheria ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056934683     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (68)

1. Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Rockville, MD: CDER, Food and Drug Administration, August 1997.
2. FIP guidelines for dissolution testing of solid oral products. Joint report of the section for official laboratories and medicines control services and the section of industrial pharmacists of the F.I.P. Pharm Ind 1997; 59: 760-766.
3. Polli JE, Rekhi GS, Augsburger LL, Shah VP. Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets. J Pharm Sci 1997; 86: 690-700.
4. Shah VP. Concept of mapping. Drug Inf J 1996; 30: 1085-1089.
5. United States Pharmacopeial Convention, Inc. The United States Pharmacopoeia (USP 23). Rockville, MD, 1995.
6. Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation and Application of In Vitro/In Vivo Correlations. Rockville, MD: CDER, Food and Drug Administration, September 1997.
7. Guidance for Industry. Immediate Release Solid Oral Dosage Forms, Scale-up and Post-approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Rockville, MD: CDER, Food and Drug Administration, November 1995.
8. Guidance for Industry. Modified Release Solid Oral Dosage Forms, Scale-up and Post-approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Rockville, MD: CDER, Food and Drug Administration, September 1997.
9. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release forms. Pharm Res 1998; 15: 11-22.
10. Langenbucher F. Parametric representation of dissolution-rate curves by the RRSBW distribution. Pharm Ind 1976; 38: 472-477.
11. Langenbucher F, Moeller H. Correlation of in vitro drug release with in vivo response kinetics. Part II: Use of function parameters. Pharm Ind 1983; 45: 629-633.
12. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol 1975; 27: 28-49.
13. Tsong Y, Hammerstrom T, Chen JJ. Multipoint dissolution specification and acceptance sampling rule based on profile modeling and principal component analysis. J Biopharm Stat 1997; 7: 423-439.
14. Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897; 19: 756-761.
15. Noyes AA, Whitney WR. Ueber die Auflösungsgeschwindigkeit von festen Stoffen in ihren eigenen Lösungen. Z Phys Chem 1897; 23: 689-692.
16. Nernst W, Brunner E. Theorie der Reaktionsgeschwindigkeit in heterogenen Systemen. Z Phys Chem 1904; 47: 52-110.
17. Levich VG. Physicochemical Hydrodynamics. Englewood Cliffs, NJ: Prentice Hall, 1962.
18. Ostwald W. Studien über die Bildung und Umwandlung fester Körper. Z Phys Chem 1897; 22: 289-330.
19. Higuchi WI, Rowe EL, Hiestand EN. Dissolution rates of finely divided powders II: Micronized methylprednisolone. J Pharm Sci 1963; 52: 162-164.
20. Harriott P. Mass transfer to particles I. Suspended in agitated tanks. Am Inst Chem Eng J 1962; 8: 93-101.
21. Higuchi WI, Hiestand EN. Dissolution rates of finely divided drug powders I. Effect of distribution of particle sizes in a diffusion-controlled process. J Pharm Sci 1963; 52: 67-71.
22. Grijseels H, Crommelin DJA, de Blaey CJ. Hydrodynamic approach to dissolution rate. Pharm Weekbl (Sci Ed) 1981; 3: 1005-1020.
23. Niebergall PJ, Goyan JE. Dissolution rate studies I. Continuous recording technique for following rapid reaction in solution. J Pharm Sci 1963; 52: 29-33.
24. Short MP, Sharkey P, Rhodes CT. Dissolution of hydrocortisone. J Pharm Sci 1972; 61: 1733-1735.
25. Carstensen JT, Musa MN. Dissolution rate patterns of log-normally distributed powders. J Pharm Sci 1972; 61: 223-227.
26. Pothisiri P, Carstensen JT. Nonsink dissolution rate equation. J Pharm Sci 1973; 62: 1468-1470.
27. Carstensen JT, Patel M. Dissolution patterns of polydisperse powders: oxalic acid dihydrate. J Pharm Sci 1975; 64: 1770-1776.
28. Pedersen PV, Brown KF. Theoretical isotropic dissolution of nonspherical particles. J Pharm Sci 1976; 65: 1437-1442.
29. Lu ATK, Frisella ME, Johnson KC. Dissolution modelling: factors affecting the dissolution rate of polydisperse powders. Pharm Res 1993; 10: 1308-1314.
30. Hixcon AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. I. Theoretical considerations. Ind Eng Chem 1931; 23: 923-931.
31. Dali MV, Carstensen JT. Effect of change in shape factor of a single crystal on its dissolution behavior. Pharm Res 1996; 13: 155-162.
32. Lai TY, Carstensen JT. Effect of shape factor on cube root dissolution behavior. Int J Pharm 1978; 1: 33-40.
33. Hintz RJ, Johnson KC. The effect of particle size distribution on dissolution rate and oral absorption. Int J Pharm 1989; 51: 9-17.
34. Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist, New York: Technomic Publishing, 1993.
35. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961; 50: 874-875.
36. Gibaldi M, Feldman S. Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to non-disintegrating dosage forms. J Pharm Sci 1967; 56: 1238-1242.
37. Dokoumetzidis A, Macheras P. A population growth model of dissolution. Pharm Res 1997; 14: 1122-1126.
38. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985; 60: 110-111.
39. Kervinen L, Yliruusi J. Modelling S-shaped dissolution curves. Int J Pharm 1993; 92: 115-122.
40. Jørgensen K, Christensen FN. Shape modelling of dissolution profiles by non-integer kinetic orders. Int J Pharm 1996; 143: 223-232.
41. Leary JR, Ross SD. Mathematical expression of tablet dissolution profiles. Int J Pharm 1983; 17: 193-201.
42. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-453.
43. Eddington ND, Marroum P, Uppoor R, Hussain A, Augsburger L. Development and internal validation of an in vitro-in vivo correlation for hydrophilic metopro-lol tartrate extended release tablet formulation. Pharm Res 1998; 15: 466-472.
44. Dawoodbhai S, Suryanarayan ER, Woodruff CW, Rhodes CT. Optimization of tablet formulation containing talc. Drug Dev Ind Pharm 1991; 17: 1343-1371.
45. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci 1969; 58: 1253-1257.
46. Goldsmith JA, Randall N, Ross SD. On the methods of expressing dissolution rate data. J Pharm Pharmacol 1978; 30: 347-349.
47. Langenbucher F. Linearization of dissolution curves by the Weibull distribution. J Pharm Pharm 1972; 24: 979-981.
48. Sathe PM, Tsong Y, Shah VP. In vitro dissolution profile comparison: statistics and analysis, model dependent approach. Pharm Res 1996; 13: 1799-1803.
49. Sathe P, Tsong Y, Shah VP. In vitro dissolution profile comparison and IVIVR. Carbamazepine case. Adv Exp Med Biol 1997; 423: 31-42.
50. Chen JJ, Tsong Y. Multiple-time-point dissolution specification for a sampling acceptance plan. J Biopharm Stat 1997; 7: 259-270.
51. Shah VP, Yamamoto LA, Schuirman D, Elkins J, Skelly JP. Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets. Pharm Res 1987; 4: 416-419.
52. Westlake WJ. Use of statistical methods in evaluation of in vivo performance of dosage forms. J Pharm Sci 1973; 62: 1579-1589.
53. Tsong Y, Hammerstrom T, Sathe P, Shah VP. Statistical assessment of mean differences between two dissolution data sets. Drug Inf J 1996; 30: 1105-1112.
54. Chow SC, Ki FYC. Statistical comparison between dissolution profiles of drug products. J Biopharm Stat 1997; 7: 241-258.
55. Ju HL, Liaw SJ. On the assessment of similarity of drug dissolution profiles-a simulation study. Drug Inf J 1997; 31: 1273-1289.
56. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol 1996; 6: 64-74.
57. Polli JE, Rekhi GS, Shah VP. Methods to compare dissolution profiles. Drug Inf J 1996; 30: 1113-1120.
58. 2 as a criterion for assessment of similarity between dissolution profiles. Drug Inf J 1997; 31: 1255-1271.
59. 2 . Pharm Res 1998; 15: 889-896.
60. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993.
61. Rescigno A. Bioequivalence. Pharm Res 1992; 9: 925-928.
62. Amidon GL, Lennernäs H, Shah VP, Crison JRA. Theoretical basis for a biophar-maceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
63. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705.
64. Nicolaides E, Galia E, Symillides M, Dressman J, Efthymiopoulos C, Reppas C. Prediction of the oral absorption of class II drugs from immediate release formulations. Proceedings of the 9th Panhellenic Pharmaceutical Conference, Athens, Greece, 1998.
65. Chinchilli VM, Elswick RK Jr. The multivariate assessment of bioequivalence. J Biopharm Stat 1997; 7: 113-123.
66. Martson SA, Polli JE. Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. Pharm Res 1997; 14: 1363-1369.
67. Galia E, Nicolaides E, Efthymiopoulos C, Reppas C, Dressman JB. Physiologically based dissolution tests: experience with two poorly soluble GlaxoWellcome drugs [abstr.]. Pharm Res 1997; 14: S-491.
68. Macheras P, Koupparis M, Tsaprounis C. Drug dissolution studies in milk using the automated flow injection serial dynamic dialysis technique. Int J Pharm 1986; 33: 125-136.